Eli Lilly plans benchmark three-part notes offering

By Aleesia Forni

Virginia Beach, Feb. 24 – Eli Lilly & Co. intends to sell a benchmark issue of notes in three parts, according to a market source and a 424B2 filed with the Securities and Exchange Commission.

The offering will include tranches due 2018, 2025 and 2045.

Deutsche Bank Securities Inc., Goldman Sachs & Co., Morgan Stanley & Co. LLC and BofA Merrill Lynch are the joint bookrunners.

Proceeds will be used to repay commercial paper issued in connection with the company’s acquisition of the animal health business of Novartis AG and for general corporate purposes.

The pharmaceutical company is based in Indianapolis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.